Targeting the cholinergic-astrocyte axis: A novel strategy for brain metastasis prevention in lung adenocarcinoma

Xiangze Li1, Kun Liu2, Ziyao Zhang1

  • 1Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Cancer Letters
|June 14, 2025
PubMed

Insights

Lung adenocarcinoma brain metastasis is linked to cholinergic metabolism. Targeting acetylcholinesterase with donepezil shows promise in preventing metastasis and improving survival.

Area of Science:

  • Oncology
  • Neuroscience
  • Metabolism

Background:

  • Brain metastasis (BM) is a severe complication of lung adenocarcinoma (LUAD) with poor outcomes.
  • Effective preventive strategies for LUAD BM are limited.
  • Cholinergic metabolism plays a role in both LUAD progression and brain function.

Purpose of the Study:

  • To investigate the role of cholinergic metabolism in the pathogenesis of LUAD brain metastasis.
  • To identify potential therapeutic targets for preventing LUAD BM.

Main Methods:

  • Analysis of RNA-sequencing data from 875 LUAD cases and validation in 280 patients.
  • Mechanistic studies involving acetylcholinesterase (AChE) and choline acetyltransferase.
  • Single-cell RNA sequencing of BM samples and in vitro experiments.
  • Pharmacological intervention with the AChE inhibitor donepezil.

Main Results:

  • Cholinergic metabolic activation is a hallmark of LUAD tumors prone to BM, associated with poor survival.
  • AChE promotes BM through immunosuppression and blood-brain barrier (BBB) disruption.
  • AChE triggers Ca2+ influx, ATP release, and astrocyte apoptosis, facilitating tumor extravasation.
  • Choline acetyltransferase enhances tumor proliferation and migration.
  • Donepezil effectively prevented BM in preclinical models.

Conclusions:

  • A targetable cholinergic metabolism-astrocyte axis drives LUAD BM organotropism.
  • Targeting AChE represents a promising strategy to intercept LUAD metastatic progression.
  • Donepezil offers a potential therapeutic approach for preventing BM in LUAD patients.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
643
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
707
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K